NCT00697216View on ClinicalTrials.gov

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

PHASE3CompletedINTERVENTIONAL

Enrollment

340

Participants

Timeline

Start Date

March 31, 1997

Primary Completion Date

March 31, 1999

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBV-MPL vaccine 208129

2-dose intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

Trial Locations (2)

Unknown

GSK Clinical Trials Call Center, Brussels

GSK Clinical Trials Call Center, Copenhagen

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY